Drugdu.com expert's response:

The development of medical device biocompatibility requires adherence to a systematic process, integrating international standards (such as the ISO 10993 series) and domestic regulations (such as the GB/T 16886 series), and implementing it in stages from preliminary preparation to continuous monitoring. The specific steps are as follows:

I. Preliminary Preparation and Risk Assessment

Clarify Device Information

Determine the intended use (e.g., implantation, contact with blood/mucous membranes/skin), duration of contact (short-term, long-term, or permanent), and material composition (main structure, coatings, connecting components, etc.).
Example: A cardiac stent requires long-term implantation in blood vessels, necessitating a focus on evaluating tissue compatibility and blood compatibility. A disposable syringe requires attention to skin irritation and cytotoxicity.

Identify Potential Risks

Analyze the biological reactions that materials may trigger, such as allergies, cytotoxicity, local inflammation, coagulation, or hemolysis.
Example: Nickel-containing metal materials may cause allergic reactions; rough-surfaced materials may damage tissue cells.

Determine Test Items

Select test types based on risk level. Common test items include:

Cytotoxicity Testing: Evaluate the impact of materials on cell growth (e.g., MTT assay).

Irritation and Sensitization Testing: Assess irritancy through skin or mucous membrane contact tests (e.g., Guinea Pig Maximization Test).

Systemic Toxicity Testing: Observe changes in organ function through animal experiments (e.g., intravenous injection in mice).

Implantation Testing: Implant materials into animals to observe local tissue reactions.

Blood Compatibility Testing: Evaluate coagulation time, hemolysis rate, platelet adhesion, and other indicators.

Genotoxicity Testing: Detect whether materials induce gene mutations or chromosomal damage.

II. Test Implementation and Data Collection

Sample Preparation

Extract representative samples from production batches, ensuring that the materials and processes are consistent with the actual product.
Clean and sterilize the samples (avoid altering physical and chemical properties) and prepare extracts or cut them into appropriate sizes according to test requirements.

In Vitro Testing

Cell Culture: Co-culture samples or extracts with cells to observe cell morphology and proliferation.

Hemolysis Testing: Mix samples with red blood cells and measure the hemolysis rate (standards typically require <5%).

In Vivo Testing (When Necessary)

Animal Experiments: For implantation tests, implant materials into animals to observe local inflammatory reactions and fibrous capsule formation.

Acute/Subchronic Toxicity Testing: Evaluate the impact of materials on the whole body system using animal models.

Data Collection and Analysis

Record data such as cell viability, skin reaction scores, and changes in blood indicators.

Determine cytotoxicity grades (non-toxic, low-toxic, moderately toxic, highly toxic) according to standards (e.g., ISO 10993-12).

III. Comprehensive Assessment and Report Writing

Comprehensive Assessment

Evaluate whether the material's biocompatibility meets standard requirements based on all test results.

If any test fails, analyze the causes and take improvement measures (e.g., optimize material formulation, surface modification).

Report Writing

The report should include sample information, test methods, test conditions, data results, and conclusions.

Example: The biocompatibility report for a certain model of cardiac stent should detail the cytotoxicity test results (cell viability >90%) and mild local tissue reactions observed in implantation tests.

Review and Archiving

Conduct an internal review of the report to ensure data accuracy and reliable conclusions.

Archive the report after approval for regulatory review or product registration purposes.

IV. Continuous Monitoring and Improvement

Post-Market Monitoring

Collect user feedback and monitor adverse events (e.g., allergies, infections, device failures).

If biocompatibility issues are identified, promptly investigate and take corrective actions (e.g., recalls, design improvements).

Regular Re-evaluation

The biocompatibility of medical devices may change with material degradation or process variations, necessitating periodic re-evaluation.

Example: Devices implanted long-term in the body require re-evaluation of chronic toxicity risk every five years.

Key Considerations

Standard Compliance: Prioritize reference to the ISO 10993 series and GB/T 16886 series standards to ensure compliant test methods.

Risk-Oriented Approach: Select test items based on the risk level of the device, with more comprehensive evaluations required for high-risk devices.

Data Comparability: Ensure that test samples are consistent with the actual product to avoid deviations in results due to material or process differences.

Dynamic Management: Biocompatibility evaluation is an ongoing process that requires updating assessment strategies based on clinical data and literature.